Leuprorelin - Generex Biotechnology Corporation/NHTherapeutics

Drug Profile

Leuprorelin - Generex Biotechnology Corporation/NHTherapeutics

Alternative Names: NH 901

Latest Information Update: 24 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Generex Biotechnology Corporation; NHTherapeutics
  • Developer Generex Biotechnology Corporation
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypogonadism
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypogonadism

Most Recent Events

  • 19 Jan 2017 Leuprorelin receives Orphan Drug status for Hypogonadism in European Union
  • 08 Sep 2015 Preclinical trials in Hypogonadism in Canada (PO)
  • 26 May 2015 Generex and NHTherapeutics agree to co-develop leuprorelin in Canada for Hypogonadism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top